```
e cediranib/cn
                                                        CEDIN/CN
                                      1
Ε1
Ε2
                                      1
                                                        CEDINOL/CN
Е3
                                       1 --> CEDIRANIB/CN
                                                        CEDIRANIB MALEATE/CN
E4
                                      1
                                       1
                                                        CEDKATHRYN A/CN
E5
                                      1
                                                        CEDKATHRYN B/CN
Ε6
                                      1
Ε7
                                                        CEDMILIN/CN
E8
                                       1
                                                        CEDMILINE/CN
E9
                                      1
                                                       CEDMILINOL/CN
E10
                                      1
                                                       CEDO 8811/CN
                                                        CEDO 8816/CN
                                      1
E11
E12
                                                        CEDO 8834/CN
                                      1
=> s e3
                                      1 CEDIRANIB/CN
L1
=> d
              ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
L1
              288383-20-0 REGISTRY
RN
              Entered STN: 08 Sep 2000
ED
              Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-indol-5-yl)oxy]
CN
              pyrrolidinyl)propoxy]- (CA INDEX NAME)
OTHER NAMES:
               4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-
CN
              yl)propoxy]quinazoline
               4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy]-6-methoxy-7-[3-(pyrrolidin-1-1)oxy-7-[3-(pyrrolidin-1-1)oxy-7-[3-(pyrrolidin-1-1)oxy-7-[3-(pyrrolidin-1-1)oxy-7-[3-(pyrrolidin-1-1)oxy-7-[3-(pyrrolidin-1-1)oxy-7-[3-(pyrrolidin-1-1)oxy-7-[3-(pyrrolidin-1-1)oxy-7-[3-(pyrrolidin-1-1)oxy-7-[3-(pyrrolidin-1-1)oxy-7-[3-(pyrrolidin-1-1)oxy-7-[3-(pyrrolidin-1-1)oxy-7-[3-(pyrrolidin-1-1-1)oxy-7-[3-(pyrrolidin-1-1-1)oxy-7-[3-(pyrrolidin-1-1-1)oxy-7-[3-(pyrrolidin-1-1-1]oxy-7
CN
              yl)propoxy]quinazoline
              AZD 2171
CN
              Cediranib
CN
              ZD 2171
CN
              790713-41-6, 557795-03-6
DR
              C25 H27 F N4 O3
MF
CI
              COM
SR
              CA
               STN Files:
LC
                                                     ADISINSIGHT, CA, CAPLUS, CASREACT, CHEMCATS, CSCHEM, EMBASE,
                     IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, PROUSDDR, RTECS*, SYNTHLINE,
                     TOXCENTER, USAN, USPAT2, USPATFULL
                            (*File contains numerically searchable property data)
```

```
=> file caplus
> file reg
=> e irinotecan/cn
                   IRINITE/CN
E1
Ε2
                   IRINOPHORE C/CN
E3
             1 --> IRINOTECAN/CN
                   IRINOTECAN HYDROCHLORIDE/CN
\mathrm{E}\,4
             1
            1
E5
                   IRINOTECAN HYDROCHLORIDE HYDRATE/CN
            1
                  IRINOTECAN HYDROCHLORIDE SESQUIHYDRATE/CN
Ε6
E7
             1
                   IRINOTECAN HYDROCHLORIDE TRIHYDRATE/CN
            1
Ε8
                   IRINOTECAN LACTONE/CN
E9
             1
                   IRINOTECAN-TETRAZOLIUM VIOLET MIXT./CN
            1
E10
                   IRINOTECAN-VINCRISTINE N-OXIDE MIXT./CN
            1
E11
                  IRIOBRONZE FINE SILVER/CN
E12
                   IRIODIN/CN
=> s e3
             1 IRINOTECAN/CN
L2
=> d
L2
    ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
     97682-44-5 REGISTRY
RN
     Entered STN: 18 Aug 1985
ED
     [1,4'-Bipiperidine]-1'-carboxylic acid,
CN
     (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-
     pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (CA INDEX NAME)
OTHER CA INDEX NAMES:
     1H-Pyrano[3', 4':6,7]indolizino[1,2-b]quinoline,
CN
     [1,4'-bipiperidine]-1'-carboxylic acid deriv.
     [1,4'-Bipiperidine]-1'-carboxylic acid,
CN
     4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-
     pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, (S)-
OTHER NAMES:
     (+)-Irinotecan
CN
CN
     Irinophore C
     Irinotecan
CN
     Irinotecan lactone
CN
FS
     STEREOSEARCH
     C33 H38 N4 O6
MF
CI
     COM
SR
     CA
LC
     STN Files:
                  ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
       CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE,
       HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE,
       MRCK*, PATDPASPC, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER,
       USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
```

Absolute stereochemistry. Rotation (+).

100 REFERENCES IN FILE CA (1907 TO DATE)

104 REFERENCES IN FILE CAPLUS (1907 TO DATE)

6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3414 REFERENCES IN FILE CA (1907 TO DATE)
72 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3431 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> e 5-fluorouracil/cn
                   5-FLUOROTRYPTOPHOL/CN
E1
                   5-FLUOROTUBERCIDIN/CN
Ε2
Е3
             1 --> 5-FLUOROURACIL/CN
                   5-FLUOROURACIL 2'-DEOXYRIBOSIDE/CN
E4
                   5-FLUOROURACIL ARABINONUCLEOSIDE 5'-PHOSPHATE/CN
             1
E5
Ε6
             1
                   5-FLUOROURACIL DEOXYRIBONUCLEOSIDE 5'-PHOSPHATE/CN
                   5-FLUOROURACIL DEOXYRIBOSIDE/CN
E7
             1
Ε8
             1
                   5-FLUOROURACIL ION(1-)/CN
E9
             1
                   5-FLUOROURACIL LITHIUM SALT/CN
             1
E10
                   5-FLUOROURACIL MONOSODIUM SALT/CN
                   5-FLUOROURACIL NITRATE/CN
E11
             1
E12
                   5-FLUOROURACIL PHOSPHORIBOSYLTRANSFERASE/CN
             1
=> s e3
             1 5-FLUOROURACIL/CN
L3
=> d
     ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
L3
     51-21-8 REGISTRY
RN
     Entered STN: 16 Nov 1984
ED
     2,4(1H,3H)-Pyrimidinedione, 5-fluoro- (CA INDEX NAME)
CN
OTHER CA INDEX NAMES:
     Uracil, 5-fluoro- (8CI)
CN
OTHER NAMES:
     2,4-Dihydroxy-5-fluoropyrimidine
CN
     2,4-Dioxo-5-fluoropyrimidine
CN
     5-Fluoracyl
CN
     5-Fluoro-2, 4(1H, 3H)-pyrimidinedione
CN
```

```
5-Fluoro-2, 4-pyrimidinedione
CN
CN
     5-Fluoropyrimidine-2,4-diol
     5-Fluorouracil
CN
CN
     5-FU
     Adrucil
CN
    Arumel
CN
CN
     Carac
CN
     Carzonal
CN
     Efudex
CN
     Efudix
CN
     Efurix
     Fluoroblastin
CN
     Fluoroplex
CN
     Fluorouracil
CN
     Flurablastin
CN
     Fluracedyl
CN
     Fluracil
CN
CN
     Fluracilum
     Fluri
CN
    Fluril
CN
     Ftoruracil
CN
CN
     FU
CN
     Kecimeton
CN
     NSC 19893
    Phthoruracil
CN
     Phtoruracil
CN
     Queroplex
CN
     Ro 2-9757
CN
     Timazin
CN
     U 8953
CN
     Ulup
CN
     1004-03-1, 79108-01-3, 4921-97-5
DR
     C4 H3 F N2 O2
MF
     COM
CI
     STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
LC
       BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS,
       CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU,
       EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,
       IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*,
       MSDS-OHS, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SPECINFO,
       SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, USPATOLD, VETU
         (*File contains numerically searchable property data)
                     EINECS**, NDSL**, TSCA**, WHO
     Other Sources:
         (**Enter CHEMLIST File for up-to-date regulatory information)
```

FAMILY ACC. NUM. COUNT:

```
21546 REFERENCES IN FILE CAPLUS (1907 TO DATE)
=> file caplus
=> d his
     (FILE 'HOME' ENTERED AT 17:49:55 ON 22 OCT 2009)
     FILE 'REGISTRY' ENTERED AT 17:50:43 ON 22 OCT 2009
                E CEDIRANIB/CN
              1 S E3
L1
     FILE 'CAPLUS' ENTERED AT 17:51:19 ON 22 OCT 2009
     FILE 'REGISTRY' ENTERED AT 17:51:28 ON 22 OCT 2009
                E IRINOTECAN/CN
              1 S E3
L2
                E 5-FLUOROURACIL/CN
L3
              1 S E3
     FILE 'CAPLUS' ENTERED AT 17:52:26 ON 22 OCT 2009
=> s 11 (L) (12 or 13)
           104 L1
          3431 L2
         21546 L3
             0 L1 (L) (L2 OR L3)
L4
=> s 11 and (12 or 13)
           104 L1
          3431 L2
         21546 L3
            26 L1 AND (L2 OR L3)
L5
=> s 15 and py<2005
      25144356 PY<2005
             1 L5 AND PY<2005
L6
=> d ibib abs hitind
     ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
L6
ACCESSION NUMBER:
                         2004:965067 CAPLUS <<LOGINID::20091022>>
DOCUMENT NUMBER:
                         141:406039
                         Combinations for the treatment of diseases involving
TITLE:
                         cell proliferation, migration or apoptosis of myeloma
                         cells, or angiogenesis
                         Hilberg, Frank; Solca, Flavio; Stefanic, Martin
INVENTOR(S):
                         Friedrich; Baum, Anke; Munzert, Gerd; Van Meel,
                         Jacobus C. A.
                         Boehringer Ingelheim International G.m.b.H., Germany;
PATENT ASSIGNEE(S):
                         Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE:
                         PCT Int. Appl., 101 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:
                         Patent
                         English
LANGUAGE:
```

21449 REFERENCES IN FILE CA (1907 TO DATE)

500 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

## PATENT INFORMATION:

```
APPLICATION NO.
    PATENT NO.
                        KIND
                               DATE
                                                                 DATE
    WO 2004096224
                       Α2
                               20041111
                                          WO 2004-EP4363
                                                                 20040424 <--
    WO 2004096224
                  A3
                               20041216
           AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
            GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
            LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,
            NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
            TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
                                        EP 2003-9587
                               20041103
                                                                 20030429 <--
    EP 1473043
                         Α1
           AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                   A1
                                                         20040424 <--
    AU 2004233576
                               20041111
                                        AU 2004-233576
                                        CA 2004-2523868
                                                               20040424 <--
    CA 2523868
                               20041111
                       A1
    EP 1622619
                       Α2
                               20060208
                                        EP 2004-729366
                                                                 20040424
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
                       А
                               20060425
                                        BR 2004-9919
    BR 2004009919
                                                                 20040424
                       Τ
                                        JP 2006-500099
    JP 2006524634
                               20061102
                                                                 20040424
                    A
    IN 2005DN04018
                               20091002
                                        IN 2005-DN4018
                                                                 20050907
                   A
    MX 2005011656
                               20051215
                                         MX 2005-11656
                                                                 20051028
                  A
    NO 2005005605
                               20051128
                                          NO 2005-5605
                                                                 20051128
                                                            A 20030429
PRIORITY APPLN. INFO.:
                                          EP 2003-9587
                                                          A 20040113
                                          EP 2004-508
                                           EP 2004-1171
                                                                 20040121
                                           WO 2004-EP4363
                                                                 20040424
                                                              W
    The present invention relates to a pharmaceutical combination for the
AB
    treatment of diseases which involves cell proliferation, migration or
    apoptosis of myeloma cells, or angiogenesis. The invention also relates
    to a method for the treatment of said diseases, comprising
    co-administration of effective amts. of specific active compds. and/or
    co-treatment with radiation therapy, in a ratio which provides an additive
    and synergistic effect, and to the combined use of these specific compds.
    and/or radiotherapy for the manufacture of corresponding pharmaceutical
    combination prepns. The pharmaceutical combination can include selected
```

protein tyrosine kinase receptor antagonists and further chemotherapeutic

IC ICM A61K031-496

=> d his

(FILE 'HOME' ENTERED AT 17:49:55 ON 22 OCT 2009)

FILE 'REGISTRY' ENTERED AT 17:50:43 ON 22 OCT 2009 E CEDIRANIB/CN

or naturally occurring semisynthetic or synthetic agents.

L1 1 S E3

FILE 'CAPLUS' ENTERED AT 17:51:19 ON 22 OCT 2009

FILE 'REGISTRY' ENTERED AT 17:51:28 ON 22 OCT 2009 E IRINOTECAN/CN

BR 2005008982

JP 2007530518

ZA 2006007555

MX 2006010758

NO 2006004755

KR 2006130763

US 20080125447

L2 1 S E3 E 5-FLUOROURACIL/CN L3 1 S E3 FILE 'CAPLUS' ENTERED AT 17:52:26 ON 22 OCT 2009 0 S L1 (L) (L2 OR L3) L4L5 26 S L1 AND (L2 OR L3) 1 S L5 AND PY<2005 L6 => s 15 and py=2005 1432022 PY=2005 3 L5 AND PY=2005 L7 => d ibib 1-3L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2005:1075607 CAPLUS <<LOGINID::20091022>> DOCUMENT NUMBER: 143:339615 AZD2171 in combination with 5-FU and/or CPT-11 for the TITLE: treatment of cancer INVENTOR(S): Wedge, Stephen Robert PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited SOURCE: PCT Int. Appl., 47 pp. CODEN: PIXXD2 Patent DOCUMENT TYPE: LANGUAGE: English FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: DATE APPLICATION NO. PATENT NO. KIND DATE \_\_\_\_ WO 2005092303 A2 20051006 WO 2005-GB1080 20050322 <--WO 2005092303 A3 20061102 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2005-225193 AU 2005225193 20051006 20050322 <--Α1 AU 2005225193 20081009 В2 20050322 <--CA 2610628 Α1 20051006 CA 2005-2610628 Α2 EP 1729808 20061213 EP 2005-729381 20050322 AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU 20070516 CN 2005-80009218 20050322 CN 1964742 Α

20070828

20071101

20080528

20061215

20080529

20061020

20061219

Α

Α

Α

Α1

Α

Α

BR 2005-8982

ZA 2006-7555

NO 2006-4755

MX 2006-10758

US 2006-594233

KR 2006-721774

JP 2007-504467

20050322

20050322

20060908

20060920

20060925

20061020

20061020

10/594,233 10/22/2009 GB 2004-6446 A 20040323 PRIORITY APPLN. INFO.: WO 2005-GB1080 W 20050322 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN L7 2005:99470 CAPLUS <<LOGINID::20091022>> ACCESSION NUMBER: DOCUMENT NUMBER: 142:197889 Fluoro substituted omega-carboxyaryl diphenyl urea for TITLE: treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases INVENTOR(S): Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott Bayer Pharmaceuticals Corporation, USA PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 68 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent English LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE WO 2005009961 A2 20050203 WO 2004-US23500 20040722 <--WO 2005009961 A3 20050331 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

SN, TD, TG AU 2004259760 20050203 AU 2004-259760 20040722 <--Α1 20050203 CA 2004-2532865 CA 2532865 A1 20040722 <--US 20050038080 A1 US 2004-895985 20050217 20040722 <--20060607 EP 2004-786091 EP 1663978 A2 20040722 EP 1663978 20071128 В1 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK BR 2004012219 Α 20060822 BR 2004-12219 20040722 CN 1856469 Α 20061101 CN 2004-80021091 20040722 20061214 JP 2006-521221 JP 2006528196 Τ 20040722 ES 2297490 Т3 20080501 ES 2004-786091 20040722 ZA 2006000609 Α 20070530 ZA 2006-609 20060120 KR 2006052866 20060519 KR 2006-701558 20060123 Α MX 2006000860 Α 20060720 MX 2006-860 20060123 20070824 IN 2006-DN402 IN 2006DN00402 Α 20060123 NO 2006000870 Α 20060407 NO 2006-870 20060222 US 2003-489102P PRIORITY APPLN. INFO.: P 20030723 US 2004-540326P P WO 2004-US23500 W 20040202 20040722 OTHER SOURCE(S): CASREACT 142:197889

OS.CITING REF COUNT: THERE ARE 16 CAPLUS RECORDS THAT CITE THIS 16

RECORD (20 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:965067 CAPLUS <<LOGINID::20091022>>

DOCUMENT NUMBER: 141:406039

TITLE: Combinations for the treatment of diseases involving

cell proliferation, migration or apoptosis of myeloma

cells, or angiogenesis

INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin

Friedrich; Baum, Anke; Munzert, Gerd; Van Meel,

Jacobus C. A.

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany;

Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.					KIND		DATE		APPLICATION NO.					DATE				
WO	2004	2004096224				<del></del>	20041111		WO 2004-EP4363						20040424			
MO	WO 2004096224				А3		20041216											
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,	GE,	
		GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	
		LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,	NO,	
		NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	ТJ,	
		TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW		
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	$ZM_{r}$	ZW,	AM,	
		AZ,	BY,	KG,	KZ,	MD,	RU,	ΤJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	
		EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	ΙΤ,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	
		SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	$\mathrm{ML}_{{}_{\!{}^{\prime}}}$	MR,	NE,	
		SN,	TD,	ΤG														
EP	1473	043			A1	20041103				EP 2003-9587					20030429			
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK		
AU 2004233576				A1		20041111 AU 2004-233576								20040424				
CA				A1				CA 2004-2523868						20040424				
ΕP	1622	1622619			A2					EP 2004-729366					20040424			
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		IE,	•	•	•	•	TR,	•	•	•	•	•						
BR 2004009919															0040			
JP 2006524634						2006			JP 2						0040			
IN 2005DN04018						2009			IN 2						0050			
MX 2005011656						2005			MX 2						0051			
NO 2005005605				A		2005	1128		NO 2								<	
ORITY APPLN. INFO.:										EP 2								
										EP 2						0040		
										EP 2						0040		
					_					WO 2						0040		
CITING REF COUNT:				12		'HERE					ECOR	DS T	HAT	CITE	THI	S		
							ECOR	•			•			_				
ERENCE COUNT:				12		THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS												
						R	RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT											